Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy
2008; Mary Ann Liebert, Inc.; Volume: 18; Issue: 3 Linguagem: Inglês
10.1089/thy.2007.0315
ISSN1557-9077
AutoresLuigi Bartalena, Lelio Baldeschi, Alison Dickinson, Anja Eckstein, Pat Kendall‐Taylor, Claudio Marcocci, Maarten P. Mourits, Petros Perros, Kostas Boboridis, Antonella Boschi, Nicola Currò, Chantal Daumerie, George J. Kahaly, Gerasimos E Krassas, Carol Lane, John H. Lazarus, Michele Marinò, Marco Nardi, Christopher Neoh, Jacques Orgiazzi, Simon H. S. Pearce, Aldo Pinchera, Susanne Pitz, Mario Salvi, Paolo Sivelli, Matthias Stahl, Georg von Arx, Wilmar M. Wiersinga,
Tópico(s)Craniofacial Disorders and Treatments
ResumoThyroidVol. 18, No. 3 Original Studies, Reviews and Scholarly DialogConsensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' OrbitopathyLuigi Bartalena, Lelio Baldeschi, Alison J. Dickinson, Anja Eckstein, Pat Kendall-Taylor, Claudio Marcocci, Maarten P. Mourits, Petros Perros, Kostas Boboridis, Antonella Boschi, Nicola Currò, Chantal Daumerie, George J. Kahaly, Gerasimos Krassas, Carol M. Lane, John H. Lazarus, Michele Marinò, Marco Nardi, Christopher Neoh, Jacques Orgiazzi, Simon Pearce, Aldo Pinchera, Susanne Pitz, Mario Salvi, Paolo Sivelli, Matthias Stahl, Georg von Arx, and Wilmar M. WiersingaLuigi BartalenaSearch for more papers by this author, Lelio BaldeschiSearch for more papers by this author, Alison J. DickinsonSearch for more papers by this author, Anja EcksteinSearch for more papers by this author, Pat Kendall-TaylorSearch for more papers by this author, Claudio MarcocciSearch for more papers by this author, Maarten P. MouritsSearch for more papers by this author, Petros PerrosSearch for more papers by this author, Kostas BoboridisSearch for more papers by this author, Antonella BoschiSearch for more papers by this author, Nicola CurròSearch for more papers by this author, Chantal DaumerieSearch for more papers by this author, George J. KahalySearch for more papers by this author, Gerasimos KrassasSearch for more papers by this author, Carol M. LaneSearch for more papers by this author, John H. LazarusSearch for more papers by this author, Michele MarinòSearch for more papers by this author, Marco NardiSearch for more papers by this author, Christopher NeohSearch for more papers by this author, Jacques OrgiazziSearch for more papers by this author, Simon PearceSearch for more papers by this author, Aldo PincheraSearch for more papers by this author, Susanne PitzSearch for more papers by this author, Mario SalviSearch for more papers by this author, Paolo SivelliSearch for more papers by this author, Matthias StahlSearch for more papers by this author, Georg von ArxSearch for more papers by this author, and Wilmar M. WiersingaSearch for more papers by this authorPublished Online:14 Mar 2008https://doi.org/10.1089/thy.2007.0315AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited bySerum microRNA as a potential biomarker for the activity of thyroid eye disease5 January 2023 | Scientific Reports, Vol. 13, No. 1Hypo vs. hyperthyroid eye disease: is there any difference?10 February 2023 | BMC Ophthalmology, Vol. 23, No. 1Non-coding RNA-mediated epigenetic alterations in Grave's ophthalmopathy: A scoping systematic reviewNon-coding RNA Research, Vol. 8, No. 3The Changes in Ocular Biomechanical Response Parameters and Intraocular Pressure After Surgical Treatment for Thyroid Eye DiseaseInvestigative Opthalmology & Visual Science, Vol. 64, No. 10Static and dynamic pupillary features in graves’ ophthalmopathy1 April 2022 | Clinical and Experimental Optometry, Vol. 106, No. 5Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression Nicola Currò, Claudio Guastella, Giacinta Pirola, Barbara Calonghi, Alessandra Bottari de Castello, Maria Chiara Fazio, Sabina di Benedetto, Valeria Minorini, Marco Daga, Andrea Contarino, Ilaria Muller, Maura Arosio, Francesco Viola, Lorenzo Pignataro, and Mario Salvi8 June 2023 | Thyroid, Vol. 33, No. 6Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy8 May 2023 | Frontiers in Endocrinology, Vol. 14Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy23 November 2022 | Journal of Nuclear Medicine, Vol. 64, No. 4Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial27 March 2023 | The Journal of Clinical Endocrinology & Metabolism, Vol. 14Inactive Graves’ orbitopathy: to treat or not to treat?15 March 2023 | Russian Ophthalmological Journal, Vol. 16, No. 1Endokrine Orbitopathie: Aktueller Stand der medikamentösen Therapie1 March 2023 | Laryngo-Rhino-Otologie, Vol. 102, No. 03Update on the surgical management of Graves’ orbitopathy6 February 2023 | Frontiers in Endocrinology, Vol. 13Teprotumumab for the treatment of thyroid eye disease29 January 2023 | Expert Opinion on Biological Therapy, Vol. 23, No. 2Hyperthyreose12 November 2022Turbo Gradient and Spin-Echo BLADE-DWI for Extraocular Muscles in Thyroid-Associated Ophthalmopathy1 January 2023 | Journal of Clinical Medicine, Vol. 12, No. 1The early diagnostic value of optical coherence tomography (OCT) and OCT angiography in thyroid-associated ophthalmopathy10 May 2023 | Therapeutic Advances in Chronic Disease, Vol. 14Automated detection of enlarged extraocular muscle in Graves’ ophthalmopathy with computed tomography and deep neural network26 September 2022 | Scientific Reports, Vol. 12, No. 1Machine learning-assisted system using digital facial images to predict the clinical activity score in thyroid-associated orbitopathy21 December 2022 | Scientific Reports, Vol. 12, No. 1Peripapillary structural and microvascular alterations in early dysthyroid optic neuropathy9 August 2022 | Eye and Vision, Vol. 9, No. 1The Relationship between Obesity-Related Factors and Graves’ Orbitopathy: A Pilot Study29 November 2022 | Medicina, Vol. 58, No. 12Recurrence of Exophthalmos after 10 Years from Orbital Floor Decompression for Dysthyroid Orbitopathy: A Case Report24 November 2021 | Indian Journal of Otolaryngology and Head & Neck Surgery, Vol. 74, No. S3Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes30 November 2022 | Indian Journal of Ophthalmology, Vol. 70, No. 12Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated OphthalmopathyJAMA Ophthalmology, Vol. 140, No. 11Non-Oncological Radiotherapy: A Review of Modern Approaches9 October 2022 | Journal of Personalized Medicine, Vol. 12, No. 10Transnasal Endoscopic Orbital Decompression Combined with an Enhanced Recovery after Surgery Protocol in Graves OphthalmopathyJournal of Ophthalmology, Vol. 2022Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves’ OrbitopathyJournal of Immunology Research, Vol. 2022Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease21 June 2022 | BMJ Open, Vol. 12, No. 6Rituximab for thyroid-associated ophthalmopathy16 June 2022 | Cochrane Database of Systematic Reviews, Vol. 2022, No. 6Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves’ Orbitopathy9 May 2022 | International Journal of Molecular Sciences, Vol. 23, No. 9Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves’ Orbitopathy26 April 2022 | Frontiers in Pharmacology, Vol. 13Retinal vascularity, nerve fiber, and ganglion cell layer thickness in thyroid eye disease on optical coherence tomography angiography17 November 2020 | Orbit, Vol. 41, No. 2Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an In Vitro Model of Graves' Orbitopathy Xing Wang, Shenglan Yang, Huijing Ye, Jingqiao Chen, Lu Shi, Lujia Feng, Xiandai Wang, Te Zhang, Rongxin Chen, Wei Xiao, and Huasheng Yang17 March 2022 | Thyroid, Vol. 32, No. 3The Changes in Optic Nerve after Orbital Decompression Surgery for Thyroid Eye Disease and Case Reports of Ischemic Optic NeuropathyBioMed Research International, Vol. 2022Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves’ Orbitopathy23 September 2020 | Ocular Immunology and Inflammation, Vol. 30, No. 2Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT1 September 2021 | Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 260, No. 2Inherited Disorders of Thyroid Hormone Metabolism Defect Caused by the Dysregulation of Selenoprotein Expression18 January 2022 | Frontiers in Endocrinology, Vol. 12Choroidal vascularity index in thyroid eye disease: comparison with controls and application in diagnosing non-inflammatory active disease4 January 2022 | Orbit, Vol. 41, No. 1Maternal Hyperthyroidism22 June 2022Transnasal endoscopic orbital decompression in the algorithm of surgical treatment of endocrine ophthalmopathyVestnik otorinolaringologii, Vol. 87, No. 3Thyroid associated orbitopathy25 May 2023 | Odisha Journal of Ophthalmology, Vol. 29, No. 2Novel observational study protocol to develop a prediction model that identifies patients with Graves’ ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy16 December 2021 | BMJ Open, Vol. 11, No. 12A pathological indicator for dysthyroid optic neuropathy: tritan color vision deficiency22 June 2021 | Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 259, No. 11Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population12 March 2021 | Ophthalmic Plastic & Reconstructive Surgery, Vol. 37, No. 6Smoking effect on peripapillary and macular microvascular structure in inactive Graves’ ophthalmopathy21 May 2021 | International Ophthalmology, Vol. 41, No. 10Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves’ orbitopathy: A preliminary studyAdvances in Medical Sciences, Vol. 66, No. 2Recent advances in thyroid eye disease: An overview15 July 2021 | IP International Journal of Ocular Oncology and Oculoplasty, Vol. 7, No. 2Predicting the Course of Graves’ Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay19 July 2021 | Hormone and Metabolic Research, Vol. 53, No. 07Leptin receptor is a key gene involved in the immunopathogenesis of thyroid‐associated ophthalmopathy14 May 2021 | Journal of Cellular and Molecular Medicine, Vol. 375Thyroid Eye Disease: Navigating the New Treatment Landscape17 March 2021 | Journal of the Endocrine Society, Vol. 5, No. 5Meibomian glands dropout in patients with inactive thyroid related orbitopathy22 April 2021 | PLOS ONE, Vol. 16, No. 4Oscillopsia After Isolated Lateral Wall Decompression Versus Balanced or 3-Wall Decompression26 May 2020 | Ophthalmic Plastic & Reconstructive Surgery, Vol. 37, No. 2Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves’ Ophthalmopathy15 February 2021 | Frontiers in Endocrinology, Vol. 11Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions Irene Campi, Nicola Currò, Guia Vannucchi, Danila Covelli, Simona Simonetta, Laura Fugazzola, Davide Dazzi, Lorenzo Pignataro, Claudio Guastella, Elisa Lazzaroni, Giacinta Pirola, and Mario Salvi12 February 2021 | Thyroid, Vol. 31, No. 2Multi-scale attention U-net for segmenting clinical target volume in graves’ ophthalmopathyNeurocomputing, Vol. 427Hyperthyreose8 December 2021Thyroid Eye DiseaseGravesʼ Orbitopathy: Current Concepts for Medical Treatment27 January 2021 | Klinische Monatsblätter für Augenheilkunde, Vol. 238, No. 01Challenges of Managing Strabismus in Thyroid Eye Disease23 March 2021 | International Ophthalmology Clinics, Vol. 61, No. 2Updates on the understanding and management of thyroid eye disease30 June 2021 | Therapeutic Advances in Ophthalmology, Vol. 13Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease5 November 2020 | Journal of the Endocrine Society, Vol. 5, No. 1Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease1 May 2021 | Clinical Ophthalmology, Vol. Volume 15Comparison of 2-wall versus 3-wall orbital decompression against dysthyroid optic neuropathy in visual function26 February 2021 | Medicine, Vol. 100, No. 8Pathogenesis and Medical Management of Thyroid Eye Disease5 August 2020Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study30 May 2020 | Journal of Endocrinological Investigation, Vol. 43, No. 12Alteration of CXCL8 pathway in the ocular surface of patients with Graves' orbitopathyAutoimmunity Reviews, Vol. 19, No. 12Clinical relevance of T lymphocyte subsets in pediatric Graves’ disease17 August 2020 | Journal of Pediatric Endocrinology and Metabolism, Vol. 33, No. 11131I Radioiodine therapy in Graves’ disease: Us et coutumes, controversies and guidelinesMédecine Nucléaire, Vol. 44, No. 4Therapie der endokrinen Orbitopathie29 July 2020 | Der MKG-Chirurg, Vol. 13, No. 3Impact of first-line treatment choice on long-term outcomes of hyperthyroid Graves’ disease patients with thyrotoxic periodic paralysisJournal of Clinical & Translational Endocrinology, Vol. 21Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy4 May 2020 | Eye, Vol. 34, No. 9Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients31 August 2020 | Journal of Clinical Medicine, Vol. 9, No. 9Tirotoxicosis e hipertiroidismoMedicine - Programa de Formación Médica Continuada Acreditado, Vol. 13, No. 13Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review10 December 2019 | Ophthalmology and Therapy, Vol. 9, No. 1The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in AdultsAnnals of Surgery, Vol. 271, No. 3Outcomes of endoscopic orbital decompression for graves’ ophthalmopathy16 June 2019 | Irish Journal of Medical Science (1971 -), Vol. 189, No. 1High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy20 November 2019 | Endocrine, Vol. 67, No. 2New insights into the pathogenesis and nonsurgical management of Graves orbitopathy30 December 2019 | Nature Reviews Endocrinology, Vol. 16, No. 2Proteomics Screening of Differentially Expressed Cytokines in Tears of Patients with Graves’ OphthalmopathyEndocrine, Metabolic & Immune Disorders - Drug Targets, Vol. 20, No. 1Patient Management in Clinical Practice26 June 2020Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinentIndian Journal of Ophthalmology, Vol. 68, No. 8Commentary: Multidisciplinary team approach to tackle thyroid eye diseaseIndian Journal of Ophthalmology, Vol. 68, No. 8Visual changes after transnasal endoscopic versus transcaruncular medial orbital wall decompression for dysthyroid optic neuropathyAuris Nasus Larynx, Vol. 46, No. 6Endoscopic orbital fat decompression for the management of proptosis in Grave’s orbitopathy using a laryngeal skimmer blade8 July 2019 | Eye, Vol. 33, No. 12Role of Magnetic Resonance Imaging in the Assessment of Active Thyroid-Associated Ophthalmopathy Patients with Long Disease DurationEndocrine Practice, Vol. 25, No. 12Metabolic Imbalance and Vitamin D Deficiency in Type 1 Diabetes in the Algerian PopulationEndocrine, Metabolic & Immune Disorders - Drug Targets, Vol. 19, No. 8Early macular and peripapillary vasculature dropout in active thyroid eye disease23 August 2019 | Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 257, No. 11When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?24 June 2019 | Endocrine, Vol. 65, No. 2Prostaglandin analogue drops for the treatment of soft tissue expansion and exophthalmos in patients with inactive thyroid eye diseaseCanadian Journal of Ophthalmology, Vol. 54, No. 4Peripapillary and Macular Vessel Density in Dysthyroid Optic Neuropathy: An Optical Coherence Tomography Angiography Study1 May 2019 | Investigative Opthalmology & Visual Science, Vol. 60, No. 6Clinical, Hormonal, and Ultrasound Characteristics of Patients with Newly Diagnosed Graves’ Disease And Different Thyroid Antibody Profiles31 May 2019 | Acta Medica Bulgarica, Vol. 46, No. 2UDZIAŁ KOMÓREK IMMUNOLOGICZNYCH W PATOGENEZIE ORBITOPATII GRAVESA7 August 2019 | Prospects in Pharmaceutical Sciences, Vol. 17, No. 3Failure of RAI Therapy in Graves' Disease Is Related to Higher Initial Serum FT4 and TRAb Levels Mary H. Samuels11 February 2019 | Clinical Thyroidology, Vol. 31, No. 2Radioiodine Therapy of Benign Thyroid Diseases22 May 2019Na+/I− Symporter Target for Thyroid Disease Imaging and Treatment12 June 2019Surgical Management of Thyroid Eye Disease: Recent Updates27 November 2019Orbital Disease in Neuro-OphthalmologyEffect of orbital decompression on dysthyroid optic neuropathyMedicine, Vol. 98, No. 3Treatment of Graves' OphthalmopathyInternational Journal of Thyroidology, Vol. 12, No. 2Treatment of adult Graves’ diseaseAnnales d'Endocrinologie, Vol. 79, No. 6Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts8 May 2018 | Scientific Reports, Vol. 8, No. 1Orbital radiotherapy plus three-wall orbital decompression in a patient with rare ocular manifestations of thyroid eye disease: case report6 February 2018 | BMC Endocrine Disorders, Vol. 18, No. 1Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial15 September 2018 | Trials, Vol. 19, No. 1Polymorphisms of FAM167A-BLK Region Confer Risk of Autoimmune Thyroid Disease Rong-hua Song, Qian Li, Xi Jia, Qiu-ming Yao, Bin Wang, and Jin-an Zhang14 November 2018 | DNA and Cell Biology, Vol. 37, No. 11Tocilizumab for thyroid eye disease27 November 2018 | Cochrane Database of Systematic Reviews, Vol. 2018, No. 11Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical TrialAmerican Journal of Ophthalmology, Vol. 195A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom18 June 2018 | Eye, Vol. 32, No. 10Jod-Basedow phenomenon: Reactivation of thyroid eye disease after contrast computed tomography12 September 2018 | African Vision and Eye Health, Vol. 77, No. 1Diffusion-weighted magnetic resonance imaging of extraocular muscles in patients with Grave's ophthalmopathy using turbo field echo with diffusion-sensitized driven-equilibrium preparationDiagnostic and Interventional Imaging, Vol. 99, No. 7-8Phenotypes of Thyroid Eye DiseaseOphthalmic Plastic & Reconstructive Surgery, Vol. 34, No. 4SThe tear cytokine profile in patients with active Graves’ orbitopathy16 November 2017 | Endocrine, Vol. 59, No. 2Autoimmune Thyroid Disease24 January 2018Orbital Decompression: Graded Surgical Approach27 June 2018Risk Factors for Structural Changes in Meibomian Gland in Thyroid Eye DiseaseJournal of the Korean Ophthalmological Society, Vol. 59, No. 7Orbitadekompression30 October 2017 | HNO, Vol. 65, No. 12Customized Minimally Invasive Orbital Decompression Surgery Improves Lower Eyelid Retraction and Contour in Thyroid Eye DiseaseOphthalmic Plastic & Reconstructive Surgery, Vol. 33, No. 6Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves’ disease for evaluation of active inflammationNuclear Medicine Communications, Vol. 38, No. 11Guidelines for Radiographic Imaging of Cranial Neuropathies1 October 2017 | Ear, Nose & Throat Journal, Vol. 96, No. 10-11Thyroidectomy for the treatment of Graves’ thyrotoxicosis in thioamide-induced agranulocytosis and sepsis4 September 2017 | Endocrinology, Diabetes & Metabolism Case ReportsClinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy Sung Hoon Yu, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, and Seong Jin Lee1 September 2017 | Thyroid, Vol. 27, No. 9Natural history of graves’ orbitopathy after treatment5 October 2016 | Endocrine, Vol. 57, No. 2Medial and mediolateral orbital decompression in intractable Graves’ OrbitopathyAuris Nasus Larynx, Vol. 44, No. 499Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy7 April 2017 | Eye, Vol. 31, No. 5Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves’ ophthalmopathy10 November 2016 | Journal of Human Genetics, Vol. 62, No. 3Retracted : Efficacy and safety of mycophenolate mofetil in patients with active moderate‐to‐severe Graves’ orbitopathy7 September 2016 | Clinical Endocrinology, Vol. 86, No. 2Thyroid eye disease: a review15 April 2021 | Clinical and Experimental Optometry, Vol. 100, No. 1Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves’ OphthalmopathyInternational Journal of Endocrinology, Vol. 2017Variants of Interleukin-22 Gene Confer Predisposition to Autoimmune Thyroid DiseaseInternational Journal of Endocrinology, Vol. 2017The Influence of Juvenile Graves’ Ophthalmopathy on Graves’ Disease CourseJournal of Ophthalmology, Vol. 2017Three Cases of Dysthyroid Orbitopathy Treated by Endoscopic Transnasal Orbital DecompressionNihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), Vol. 56, No. 4Patología tiroidea en atención primariaFMC - Formación Médica Continuada en Atención Primaria, Vol. 23Cost–utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ diseaseEuropean Journal of Endocrinology, Vol. 175, No. 6Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy30 June 2016 | American Journal of Neuroradiology, Vol. 37, No. 11Graves’ DiseaseNew England Journal of Medicine, Vol. 375, No. 162016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis Douglas S. Ross, Henry B. Burch, David S. Cooper, M. Carol Greenlee, Peter Laurberg, Ana Luiza Maia, Scott A. Rivkees, Mary Samuels, Julie Ann Sosa, Marius N. Stan, and Martin A. Walter1 October 2016 | Thyroid, Vol. 26, No. 10Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy22 March 2016 | Endocrine, Vol. 54, No. 1Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients not Treated with Orbital RadiotherapyEndocrine Practice, Vol. 22, No. 10HyperthyroidismThe Lancet, Vol. 388, No. 10047Socioeconomic Disparities in the Presentation and Treatment of Graves’ Disease and Thyroid Eye Disease6 July 2016 | Seminars in Ophthalmology, Vol. 31, No. 4Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy17 February 2016 | Journal of Endocrinological Investigation, Vol. 39, No. 6TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy PathogenesisThe Journal of Clinical Endocrinology & Metabolism, Vol. 101, No. 6Graves’ disease syndrome: a need for unified therapy7 July 2016 | Journal of Translational Internal Medicine, Vol. 4, No. 2Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapyReports of Practical Oncology & Radiotherapy, Vol. 21, No. 3Graves’ ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature14 October 2015 | Wiener klinische Wochenschrift, Vol. 128, No. 7-8Botulinum toxin injection for restrictive myopathy of thyroid-associated orbitopathy: success rate and predictive factorsJournal of American Association for Pediatric Ophthalmology and Strabismus, Vol. 20, No. 2Evaluation of Corneal Biomechanical Properties in Patients With Thyroid Eye Disease Using Ocular Response AnalyzerJournal of Glaucoma, Vol. 25, No. 3Management of Strabismus in Thyroid Eye Disease28 July 2016Graves’ OphthalmopathyClinical assessment of patients with thyroid eye diseaseBritish Journal of Hospital Medicine, Vol. 77, No. 1Management of patients with thyroid eye diseaseBritish Journal of Hospital Medicine, Vol. 77, No. 1Is modified clinical activity score an accurate indicator of diplopia progression in Graves’ orbitopathy patients?Endocrine Journal, Vol. 63, No. 12Two Cases of Optic Nerve Neuropathy from Graves’ Ophthalmopathy Treated by Endoscopic Orbital DecompressionNihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), Vol. 55, No. 2Current Trends in the Management of Thyroid OphthalmopathyHanyang Medical Reviews, Vol. 36, No. 3Endokrine Orbitopathie16 November 2015 | Spektrum der Augenheilkunde, Vol. 29, No. 5-6Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiationThe British Journal of Radiology, Vol. 88, No. 1056Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement Petros Perros, Colin M. Dayan, A. Jane Dickinson, Daniel G. Ezra, Janis L. Hickey, Christoph Hintschisch, George Kahaly, John H. Lazarus, Marian Ludgate, Beate Bartès, Caroline J. MacEwen, Anna L. Mitchell, Dan Morris, Nicole O'Connor, Simon H. Pearce, Geoffrey E. Rose, Mario Salvi, Wilmar M. Wiersinga, Alyson Williamson, and 6 November 2015 | Thyroid, Vol. 25, No. 11Assessing quality of life in Taiwanese patients with Graves' ophthalmopathyJournal of the Formosan Medical Association, Vol. 114, No. 11Euthyroid Graves’ Ophthalmopathy with Negative Autoantibodies1 November 2015 | Journal of the Korean Neurological Association, Vol. 33, No. 4Common Immunosuppressive Monotherapy for Graves’ Ophthalmopathy: A Meta-Analysis15 October 2015 | PLOS ONE, Vol. 10, No. 10Decreased serum level of IL-7 in patients with active Graves’ diseaseCytokine, Vol. 75, No. 2Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy Katharina A. Ponto, Harald Binder, Tanja Diana, Nina Matheis, Anna F. Otto, Susanne Pitz, Norbert Pfeiffer, and George J. Kahaly5 August 2015 | Thyroid, Vol. 25, No. 8Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy4 March 2015 | Journal of Endocrinological Investigation, Vol. 38, No. 7Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves’ ophthalmopathy15 January 2015 | Endocrine, Vol. 49, No. 2Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy18 January 2015 | Journal of Endocrinological Investigation, Vol. 38, No. 6Thyroid surgery for treatment of Graves’ disease complicated by ophthalmopathy: a comprehensive review1 February 2015 | Expert Review of Endocrinology & Metabolism, Vol. 10, No. 3Blood–aqueous barrier integrity in patients with Graves’ ophthalmopathy (GO), before and after rehabilitative surgery13 February 2015 | Eye, Vol. 29, No. 4Role of the Underlying Thyroid Disease on the Phenotype of Graves' Orbitopathy in a Tertiary Referral Center Marenza Leo, Francesca Menconi, Roberto Rocchi, Francesco Latrofa, Eleonora Sisti, Maria Antonietta Profilo, Barbara Mazzi, Eleonora Albano, Marco Nardi, Paolo Vitti, Claudio Marcocci, and Michele Marinò9 March 2015 | Thyroid, Vol. 25, No. 3Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves’ orbitopathy10 January 2015 | Journal of Endocrinological Investigation, Vol. 38, No. 2Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective StudyInternational Journal of Endocrinology, Vol. 2015Hypothyroxinemia, Hyperthyrotropinemia, and Radioiodine: Partners in Crime Against Graves Orbitopathy?AACE Clinical Case Reports, Vol. 1, No. 2Epidemiology and Genetic Factors in Graves’ Disease and Graves’ OphthalmopathyManagement of Hyperthyroidism in the Setting of Thyroid Eye Disease24 October 2014Diagnosis and Endocrine Management of Graves’ Disease24 October 2014Pregnancy and Childhood Thyroid Eye Disease24 October 2014The Role of Serum C-Reactive Protein Measured by High-Sensitive Method in Thyroid Disease4 May 2014 | Archivum Immunologiae et Therapiae Experimentalis, Vol. 62, No. 6Thyroid Eye DiseaseJournal of Neuro-Ophthalmology, Vol. 34, No. 4Thyroid Eye DiseaseJournal of Neuro-Ophthalmology, Vol. 34, No. 4Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy4 April 2014 | Clinical & Experimental Ophthalmology, Vol. 42, No. 8Safety and Efficacy of Combined Immunosuppression and Orbital Radiotherapy in Thyroid-Related Restrictive Myopathy: Two-Center Experience25 January 2018 | European Journal of Ophthalmology, Vol. 24, No. 6Glucocorticoid Regimens for Prevention of Graves' Ophthalmopathy Progression Following Radioiodine Treatment: Systematic Review and Meta-Analysis Shachaf Shiber, Hadas Stiebel-Kalish, Ilan Shimon, Alon Grossman, and Eyal Robenshtok10 October 2014 | Thyroid, Vol. 24, No. 10Transnasal endoscopic orbital decompression: 15-year clinical experience in Southern TaiwanJournal of the Formosan Medical Association, Vol. 113, No. 9Somatostatin analogues for thyroid associated ophthalmopathy25 July 2014Management of Graves' DiseaseEndocrinology and Metabolism Clinics of North
Referência(s)